The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

Johns Hopkins researchers identified a new target for treating Alzheimer’s disease by focusing on a protein that produces tiny amounts of hydrogen sulfide in healthy brain cells.

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of ...

Richard Silverman, PhD, is a Northwestern University chemist whose name bears the building. His experimentation led to the ...

Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Jia’s team developed a protocol to improve the screening of protein pockets. This involved identifying the pockets, removing ...

Researchers have identified a single protein whose absence can cripple tumors in mice, slowing their growth and in some cases ...

Nearly 1 in 7 adults in the United States lives with chronic kidney disease, a condition that often advances quietly until ...

Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems to eliminate disease-causing proteins. Innovators are making rapid and ...